© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Drug costs
Zynteglo May Herald “New Dawn” of Many Seven-Figure Gene Therapies
August 05, 2022
An OptumRx drug pipeline report highlights Zynteglo, a curative gene therapy treatment for beta-thalassemia, and Skysona, a gene therapy for a cerebral adrenoleukodystrophy. FDA approval decision are imminent for both. Price tags of $2 million are expected.
Uninsured Diabetes Patients Can Now Purchase Lower-Cost Insulin Through Optum Store
August 01, 2022
Those living with diabetes who don't have insurance will pay $35 for a 30-day supply of Sanofi U.S. insulins.
Patients With Cancer Faced Heightened Economic, Social, Psychological Impacts From COVID-19
June 15, 2022
A review of multiple studies found the COVID-19 exacerbated the economic, social and psychological difficulties that patients with cancer were already facing because of their cancer.
Review Paper Argues for Broader Use of Riabni, a Rituxan Biosimilar
June 03, 2022
The review, partly funded by Amgen, the maker of Riabni, makes the case for using the biosimilar to Rituxan for all indications of the originator.
The CMS Spend on Accelerated Approval Drugs. Is It Time To Tap the Brakes?
May 27, 2022
Two studies published this week documented the billions that Medicare and Medicaid spend on drugs that have been granted accelerated approval by the FDA based on surrogate end points. A study reported today in JAMA Health Forum found that only 6 of the 22 confirmatory trials used clinical outcomes.
KFF Drug Cost Panelists Discuss Rebates, Compulsory Licensing and COVID-19 Vaccine Development
May 23, 2022
Kirsten Axelsen, Richard Frank and Rachel Sachs agreed that the rapid development of the COVID-19 vaccines was a government-business success story. There was less to celebrate as the Kaiser Family Foundation panelists also unpacked the legal issues and economic consequences of drug rebates, international reference pricing, high deductible health coverage and compulsory licensing.
Patterns in New Formulation Approvals Suggest “Evergreening” by Drugmakers, Researchers Report
May 23, 2022
Findings in JAMA Health Forum show that new formulations were more likely for blockbuster drugs and drugs that received accelerated approval. Proxy measures of clinical usefulness and other elements of therapeutic value were not associated with new formulations.
Specialty Pharmacy Controls Limit Patient Access, Fein and Long Explain: 2022 Asembia Specialty Pharmacy Summit
May 04, 2022
In their general session, Adam J. Fein, PhD of Drug Channels Institute, and Doug Long of IQVIA reviewed the current specialty pharmacy space, ongoing trends and future expectations.
ICER: Cosela Doesn’t Meet Health Benefit-Price Benchmark
March 17, 2022
ICER also reviewed, plinabulin, which is development chemotherapy-induced neutropenia (CIN) and would achieve common thresholds for cost-effectiveness if priced between $1,100 and $1,600 per dose.